Truist analyst Joon Lee initiated coverage of Larimar Therapeutics (LRMR) with a Buy rating and $18 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics Aligns Executive Incentives with Milestones
- Market ‘misinterpreting’ Larimar data, selloff ‘overdone,’ says Citi
- Larimar Therapeutics selloff a buying opportunity, says JonesResearch
- Larimar Therapeutics trading resumes
- Larimar Therapeutics trading halted, volatility trading pause
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue